Quote:ome information on WISP-1 is posted below. Ohm20 might want to comment further, about comparison to Leronlimab. It looks like it may have some pretty serious side effects. This information was generated by Google AI.
WISP-1 (Wnt1-inducible signaling pathway protein 1) primarily functions by interacting with specific cell surface receptors, leading to the activation of signaling pathways like the MAPK and PI3K/Akt pathways, which in turn promote cellular processes such as proliferation, migration, invasion, and extracellular matrix production, often playing a role in tissue development, fibrosis, and cancer progression; its mechanism of action largely involves binding to proteoglycans like decorin and biglycan to modulate its interaction with target cells and influence cellular behavior.
The pathway for WISP-1 is b-catenin> WNT1 > WISP-1. Activated CCR5 increases b-catenin and it's a circular pathway. Blockade of CCR5 would decrease b-catenin and by association decrease WISP-1. Once again pharmas are looking at the lower level proteins rather than the higher level processes that control them.
12
